08.31.15
Salt Lake City, Utah-based Perseon Corporation has begun a multi-organ in vivo ablation zone study for its Microthermx microwave ablation system designed to provide ablation volumes based on different antenna configurations and varying ablation times in the liver, kidney and lung.
The technology evaluation, which will take place at the University of Louisville in Kentucky, will evaluate both laparoscopic and open surgical approaches with Microthermx, which are typical treatment regimens for energy ablation. Evaluating ablations in the chosen organs, liver, lung, and kidney, corresponds with today’s most common usage for energy ablation.
“The basis for initiating this study was to conduct an analysis of multi-probe Microthermx’ Synchronous Wave Alignment Technology, which is unique in the field of microwave energy ablation,” said Robert Martin, M.D., Ph.D., study director and principal investigator. “The idea that two antennas can be placed in multiple configurations—not exactly parallel to each other—and still provide an efficient ablation is a difference maker in a field where ablation zones can vary to great degrees with systems that require precise positioning.”
This study is part of Perseon’s Inspire 2017 campaign, which was created to strengthen the use of microwave ablation in cancer care and gather relevant clinical data to support the movement.
“This trial is pivotal for Perseon, as it marks the first in vivo trial of its kind for Microthermx,” said Brian A. Meltzer, chief medical officer of Perseon. “The push for real world results reinforces our commitment to clinically relevant data and further shows how our Synchronous Wave Alignment Technology provides added efficiency for physicians in the field of energy ablation.”
Perseon makes ablation technology to treat cancer.
The technology evaluation, which will take place at the University of Louisville in Kentucky, will evaluate both laparoscopic and open surgical approaches with Microthermx, which are typical treatment regimens for energy ablation. Evaluating ablations in the chosen organs, liver, lung, and kidney, corresponds with today’s most common usage for energy ablation.
“The basis for initiating this study was to conduct an analysis of multi-probe Microthermx’ Synchronous Wave Alignment Technology, which is unique in the field of microwave energy ablation,” said Robert Martin, M.D., Ph.D., study director and principal investigator. “The idea that two antennas can be placed in multiple configurations—not exactly parallel to each other—and still provide an efficient ablation is a difference maker in a field where ablation zones can vary to great degrees with systems that require precise positioning.”
This study is part of Perseon’s Inspire 2017 campaign, which was created to strengthen the use of microwave ablation in cancer care and gather relevant clinical data to support the movement.
“This trial is pivotal for Perseon, as it marks the first in vivo trial of its kind for Microthermx,” said Brian A. Meltzer, chief medical officer of Perseon. “The push for real world results reinforces our commitment to clinically relevant data and further shows how our Synchronous Wave Alignment Technology provides added efficiency for physicians in the field of energy ablation.”
Perseon makes ablation technology to treat cancer.